TrustTSC 3001 (1042-TSC-3001)
Project Description:
Title: TrustTSC 3001 (1042-TSC-3001): A phase 3, double-blind, randomized, placebo-controlled trial of adjunctive Ganaxolone (GNX) treatment in children and adults with Tuberous Sclerosis Complex (TSC)-related epilepsy
Role: Site PI
Funding: Marinus Pharmaceuticals
2022-present
Summary: This is a prospective, double-blind, randomized placebo-controlled study to evaluate the efficacy and safety of adjunctive Ganaxolone therapy in children and adults with refractory epilepsy associated with Tuberous Sclerosis Complex.
Core Function(s):
Training Trainees, Continuing Education/Community Training
Area of Emphasis
Education & Early Intervention, Child Care-Related Activities, Other
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
Other
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A